Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Gastroesophageal reflux disease (GERD) - symptomatic relief and healing of erosive esophagitis.
* Zollinger-Ellison syndrome and other conditions of gastric hypersecretory states.
* Prevention of NSAID-induced gastric ulcers.
## Adult Dosing
* **GERD/Erosive Esophagitis:** 40 mg orally or intravenously once daily. For severe esophagitis, may be increased to 40 mg twice daily. Duration of treatment varies based on indication and healing.
* **Maintenance of Healing of Erosive Esophagitis:** 40 mg orally once daily.
* **Hypersecretory Conditions (e.g., Zollinger-Ellison Syndrome):** Starting dose is typically 40 mg orally or intravenously twice daily. Doses may need to be increased up to 240 mg per day divided into doses.
* **Prevention of NSAID-Induced Gastric Ulcers:** 40 mg orally once daily.
## Pediatric Dosing
* **GERD (Erosive Esophagitis):**
* **12 to 17 years:** 40 mg orally once daily for up to 8 weeks.
* **5 to 11 years:** 20 mg orally once daily for up to 8 weeks. For more severe esophagitis, 40 mg once daily may be considered.
* **Less than 5 years:** Safety and efficacy not established by FDA. Some sources suggest 0.5 to 1.2 mg/kg/day orally divided once or twice daily, with a maximum of 40 mg/day. Dosing for this age group often depends on clinical judgment and local protocols.
## Dose Adjustments
No specific dose adjustments are typically required for hepatic or renal impairment, though caution is advised in severe hepatic impairment.
## Contraindications
* Known hypersensitivity to pantoprazole, any component of the formulation, or other substituted benzimidazoles.
## Adverse Effects
Common: Headache, diarrhea, nausea, abdominal pain, dizziness, flatulence.
Serious: Clostridium difficile-associated diarrhea, bone fractures (hip, wrist, spine) with long-term use, vitamin B12 deficiency, hypomagnesemia, lupus erythematosus (cutaneous and systemic).
## Key Drug Interactions
* **Drugs dependent on gastric pH for absorption:** Ketoconazole, itraconazole, iron salts, ampicillin esters, erlotinib, mycophenolate mofetil.
* **Methotrexate:** PPIs may increase methotrexate levels.
* **CYP2C19 substrates:** Clopidogrel (pantoprazole may reduce the efficacy of clopidogrel).
## Monitoring
* Monitor for signs and symptoms of hypomagnesemia (e.g., tremor, muscle cramps, seizures).
* Consider periodic magnesium levels, especially in patients on long-term therapy or concomitant diuretic/digoxin use.
* Monitor for signs of C. difficile infection.
* Monitor bone mineral density in patients at risk for osteoporosis.
## Clinical Pearls
* Administer pantoprazole oral suspension or delayed-release tablets 30 minutes before a meal.
* IV administration: Reconstitute and infuse over 15 minutes.
* Long-term PPI use is associated with increased risk of fractures, C. difficile infection, B12 deficiency, and hypomagnesemia. Use the lowest effective dose for the shortest duration necessary.
**Disclaimer:** This information is for educational purposes only and does not constitute prescribing advice. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions.
